Exploring Pharmaceutical Mass Customization

Doctoral thesis, 2022

The core purpose of therapeutic pharmaceutical products is to induce responses to various diseases in patients and thereby bring societal value; however, unmet medical needs currently prevail. Conventional treatment of these products predominantly embraces a one-size-fits-all design and is manufactured in a mass-production context. A mass-production context is driven by economies of scale, however, a one-size-fits-all product design challenges the satisfaction of individual patient needs. Pharmaceutical product customization thus aims to satisfy individuals’ treatment needs and thereby improve their therapeutic outcome; however, this implies a high product variety and low-volume production environment which challenges the cost-effective production with current mass-production platforms.

To address this challenge of achieving the cost-effective production of customized pharmaceutical products, this thesis explores a unified approach to cost-effective design, manufacturing and supply of customized pharmaceutical products. For this purpose, the mass customization principles of product modularization, process flexibility and postponement are adopted and adapted in a pharmaceutical production context.

This thesis proposes methodologies to design and model customized pharmaceutical products and production systems in a unified manner. Furthermore, customized product designs are proposed using product modularization as a design strategy and reconfigured pharmaceutical supply chain (SC) archetypes using postponement as a strategy for the cost-effective design, manufacturing and supply.

The findings suggest that an increased degree of modularization in the pharmaceutical product increases the patient benefit and thus improves therapeutic patient outcomes. In addition, current mass production platforms do not display the process flexibility required for the cost-effective production of customized pharmaceutical products. Moreover, with an increased degree of postponement, opportunities for reduced production costs in the SC emerge. Finally, the cost-effective customization of pharmaceutical products requires an integrated approach of product modularization and postponement. While modeling the production system, this thesis, however, considers an SC from the manufacturer to the pharmacy and patient assessing contemporary cost-effectiveness. Future research directions should investigate societal consequences from a wider, spatial and temporal, health care system perspective.